A Phase I Dose Escalating Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of TKI258 [dovitinib] in Subjects With Acute Myeloid Leukemia.
Phase of Trial: Phase I
Latest Information Update: 29 Jun 2010
At a glance
- Drugs Dovitinib (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- 12 Oct 2008 Acutal patient numbers, start date, and end date updated as reported by ClinicalTrials.gov.
- 07 Dec 2007 Status change
- 25 Aug 2006 New trial record.